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Abstract
Phosphatidylinositol Glycan Anchor Biosynthesis class H (PIGH) is an essential player in
the glycosylphosphatidylinositol (GPI) synthesis, an anchor for numerous cell
membrane-bound proteins. PIGH deficiency is a newly described and rare disorder
associated with developmental delay, seizures and behavioral difficulties. Herein, we
report three new unrelated families with two different bi-allelic PIGH variants, including
one new variant p.(Arg163Trp) which seems associated with a more severe phenotype.
The common clinical features in all affected individuals are developmental delay/intel-
lectual disability and hypotonia. Variable clinical features include seizures, autism spec-
trum disorder, apraxia, severe language delay, dysarthria, feeding difficulties, facial
dysmorphisms, microcephaly, strabismus, and musculoskeletal anomalies. The two sib-
lings homozygous for the p.(Arg163Trp) variant have severe symptoms including pro-
found psychomotor retardation, intractable seizures, multiple bone fractures, scoliosis,
loss of independent ambulation, and delayed myelination on brain MRI. Serum iron
levels were significantly elevated in one individual. All tested individuals with PIGH
deficiency had normal alkaline phosphatase and CD16, a GPI-anchored protein
(GPI-AP), was found to be decreased by 60% on granulocytes from one individual. This
study expands the PIGH deficiency phenotype range toward the severe end of the
spectrum with the identification of a novel pathogenic variant.
K E YWORD S
alkaline phosphatase, delayed myelination, developmental delay, epilepsy, GPI, hypotonia,
IGD, iron overload, language delay
Camille Tremblay-Laganière and Rauan Kaiyrzhanov contributed equally to this study.
Received: 19 August 2020 Revised: 27 October 2020 Accepted: 2 November 2020
DOI: 10.1111/cge.13877
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Clinical Genetics. 2020;1–5. wileyonlinelibrary.com/journal/cge © 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd 1
1 | INTRODUCTION
It is estimated that about 1% of the human proteome is anchored to the
cell membrane by a glycosylphosphatidylinositol (GPI) anchor.1 GPIs are
synthetized initially by the GPI-N-acetylglucosaminyltransferase (GPI-
GnT) on the cytoplasmic membrane of endoplasmic reticulum (ER).2 GPI-
GnT is a complex comprising PIGA, PIGC, PIGH, PIGP, PIGQ, and PIGY
subunits. Absent or abnormal GPI-anchoring can lead, among other fates,
to intracellular degradation or extracellular secretion of the GPI-anchored
proteins (GPI-APs).3 Because of GPI-Aps' importance in embryogenesis
and neurogenesis, disruption of GPI biosynthesis results most commonly
in developmental delay/intellectual disability (DD/ID), seizures, dysmor-
phisms and other nervous system abnormalities such as hypotonia, a
group of diseases called inherited GPI deficiency disorders (IGDs).2
Phosphatidylinositol Glycan Anchor Biosynthesis class H (PIGH,
MIM reference number 618010) is an essential component for
GPI-GnT enzymatic activity in yeast.4 There are only three reported
cases from two families of individuals with bi-allelic PIGH variants in
the literature.5,6 Those individuals had DD/ID, seizures, behavioral dif-
ficulties, autism spectrum disorder, delayed language, microcephaly,
mild dysmorphic features, normal alkaline phosphatase and non-
specific brain MRI findings. Herein, we report three new unrelated
families with two different bi-allelic PIGH variants, including one that
was never reported before: p.(Arg163Trp).
2 | RESULTS
The core phenotype in this case series is DD/ID combined with hypoto-
nia. Family pedigrees are presented in Figure 1A. Table 1 compares fea-
tures from previously reported individuals to individuals described herein.
The affected individual in Family 1 is a 4-year-old boy with an
unremarkable antenatal and neonatal history. He has an asymptomatic
sister and was born to non-consanguineous parents of Indian origin.
He did not have a motor delay but language acquisition was signifi-
cantly impaired. No speech or babbling were noted at 18 months old,
and he is currently nonverbal. There was no history of seizures. He
has a confirmed autism spectrum disorder. His neuromuscular exami-
nation at 18 months old revealed apraxia, dysarthria, and hypotonia.
Height was 84.5 cm (80th percentile), weight was 11.3 kg (37th per-
centile) and head circumference was 48.5 cm (72nd percentile). The
rest of the physical examination was unremarkable. CGH microarray
was normal. Whole exome sequencing showed KIAA2022 (p.T1254N,
c.C3761A) and BCOR (p.L532S, c.T1595C) maternally inherited VUSs
(variants of uncertain significance).
Family 2 presented with two affected siblings born to non-
consanguineous parents of Guatemalan descent. The proband is a
20-year-old male, who was born at 38 weeks of gestation to a mother
with insulin-controlled gestational diabetes. He was remarkably
underweight at the seventh percentile at birth and fourth percentile
at 18 years old. Severe DD/ID and poorly controlled seizures were
the predominant neurological features. He began having focal seizures
on the 10th day of life with mostly nocturnal episodes lasting for
1-2 minutes or longer. EEG at 18 years old was within the broad limits
of normal in the awake state but excessive beta waves were present
throughout the tracing. Trials of phenobarbital, phenytoin, carbamaze-
pine, valproic acid, and zonisamide did not permit to achieve seizure
control. He is currently on a combination of topiramate, levetiracetam,
and clonazepam and continues to have 2-3 seizures a month. He had
a history of multiple bone fractures due to osteopenia and a scoliosis,
which was surgically corrected by posterior fusion from T2 to the pel-
vis. His independent ambulation was impaired, requiring a wheelchair,
and he was nonverbal. Upon examination, apraxia, microcephaly (head
circumference below first percentile) and significant overbite were
present. Feeding was through a gastrostomy tube and he suffered
constipation. He was found to have esotropia, hypotonia, and upper
limbs dystonia coupled with flexible joints and lumbar lordosis. The
rest of the physical examination was unremarkable. Renal ultrasound
and plasma alkaline phosphatase levels were normal. Brain MRI at
2 years old revealed delayed myelination and diffuse abnormal signal
in the right temporal lobe. His affected brother is 7 years old. He was
also born full term, and the pregnancy was complicated by insulin-
controlled gestational diabetes. The neonatal period was unremarkable.
He had severe DD/ID with early-onset seizures like his brother. Focal
seizures began at 3 months old. Valproic acid and diazepam were
unsuccessful. He had been seizure free for several years with
topiramate, levetiracetam and clonazepam. EEG at 4 years old demon-
strated interictal spikes with a slow background. He had constipation,
and his diet is restricted to pureed foods. The physical exam showed a
myopathic facies with anteverted nares, esotropia and microcephaly
(head circumference below first percentile). He also had flexible joints
with scoliosis, hypotonia, dystonia and apraxia. He is non-verbal and
wheelchair bound. MRI showed delayed myelination at 1 year old.
Hearing exam, amino acids, urine organic acids, acylcarnitine, and very
long-chain fatty acid levels were normal for both siblings.
The proband in Family 3 is a 4-year-old girl, who is the first child
of a consanguineous couple of Azerbaijani origin. She was born full-
term after an uneventful pregnancy but suffered asphyxia at birth.
Her neonatal physical measurements were normal. She had febrile sei-
zures at 7 months old and mild motor delay. From one and half year
old, she developed afebrile seizures including absence and generalized
tonic seizures. Her EEG showed generalized spike-and-wave com-
plexes, and the seizures failed to respond to various antiepileptic med-
ications including topiramate, ethosuximide, phenobarbital, and
levetiracetam. Only valproic acid 600 mg/day was effective, and she
is currently seizure-free on this medication with a normalized EEG.
She is verbal, speaks in full sentences, although there is a very mild
cognitive delay with no autistic features and no behavioral abnormali-
ties. Except for hypotonia, her physical examination along with her
brain MRI was unremarkable. She has normal head circumference.
Plasma alkaline phosphatase levels were within a normal range
(342.0 U/L) and plasma iron was elevated (34.3 μmol/L) with normal
ferritin (17.5 ng/mL). She did not receive iron supplementation. She
has one sibling, who is currently unaffected.
The four affected individuals from three families described here
were homozygous for one PIGH missense variants (p.(Ser103Pro) for
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Families 1 and 3, and p.(Arg163Trp) for Family 2). Figure 1B shows
localization of these variants across the protein in relation with the
GPI-GIcNAc transferase complex domain. The variant p.(Ser103Pro)
was previously reported.6 One additional variant p.(Met1Leu) was
previously published and resulted in an alternative in-frame start in
exon 2 (Met63).5 The variant p.(Ser103Pro) was predicted to be a
VUS by ACMG classification and has a CADD score of 27.7 (See
Table S1). Pathogenicity prediction tools from Varsome were divided
F IGURE 1 A, Pedigrees and genotypes of families with Bi-allelic PIGH variants. B, PIGH protein structure and location of variants. Figure from
ProteinPaint. Variants from affected individuals described here are in blue. Previously published pathogenic variants are in red.5,6 C, FACS from
blood cells of one affected individual GPI-AP surface levels (FLAER, CD16, CD55, and CD59) on granulocytes for individual 1 [Colour figure can
be viewed at wileyonlinelibrary.com]
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in their predictions (see Table S1). The variant p.(Arg163Trp) was
predicted to be a VUS by ACMG classification and has a CAAD score of
32. More tools predicted the variant to be pathogenic than not. Both vari-
ants occur in residues well conserved across vertebrates (See Figure S1).7
A blood sample was obtained from Individual 1, and granulocytes
were tested for GPI-AP levels and compared to those of his unaf-
fected heterozygous parents (Figure 1C). FLAER, CD55 and CD59
levels were unchanged but CD16 levels were decreased by 60%.
3 | DISCUSSION
Previously reported individuals with PIGH deficiency had cognitive per-
formance allowing attending mainstream school with support.5,6 In our
study, three individuals were nonverbal with moderate or severe
DD/ID. Autism spectrum disorder/behavioral difficulties, which was a
predominant feature in the previously reported cases, was only present
in one individual from this series. Brain MRI in a previous study showed
subtle nonspecific findings and PET revealed increased glucose uptake
in the temporal regions in one individual.5 Herein, we found delayed
myelination in two siblings from one family and diffuse abnormal signal
in the right temporal lobe in one, whereas in others brain imaging
appeared normal. Delayed myelination was also observed in individuals
with PIGA and PIGQ deficiency.2,8 Esotropia, dysarthria, dystonia, and
spinal deformities coupled with osteopenia leading to multiple fractures,
loss of independent ambulation, and elevated serum iron levels are
among the previously unreported symptoms associated with PIGH defi-
ciency in our series. Systemic iron overload was previously described in
one family with neurodegeneration, dermatosis including ichthyosis and
pathogenic variants in PIGA, another GPI-GnT component.9 The
author's hypothesis was that some proteins involved in iron homeosta-
sis, notably hemojuvelin, are GPI-anchored and disruption of their
anchor could result in a dysregulation leading to progressive systemic
iron overload. One individual from a previous study had dry skin
suspected to be ichthyosis but serum iron or ferritin were not
measured—ichthyosis is also seen with PIGL deficiency.2,5 Craniofacial
dysmorphisms, strabismus, and musculoskeletal anomalies, namely scoli-
osis and osteopenia/osteoporosis are often seen in other IGDs. In con-
trast with other IGDs, all tested individuals with PIGH deficiency had
normal alkaline phosphatase which has a GPI-anchor form.2,5
Drawing genotype-phenotype correlations in PIGH deficiency is diffi-
cult due to the limited number of reported cases. However, all individuals
with p.(Ser103Pro) have hypotonia, mild to moderate DD/ID with variable
language impairment and seizures. The individuals from Family 2 (homozy-
gous p.(Arg163Trp)) in our report have the most severe phenotype com-
pared to all other affected individuals, including those from the literature.
Surprisingly, Arg163, in contrast to Ser103, is outside the GPI-GIcNAc
transferase complex and is closer to the PIGH C-terminal end (Figure 1B).
Nevertheless, the variant could affect the protein's interactions, localiza-
tion, stability, or indirectly affect its enzymatic activity. This outlines the
need for further characterization of PIGH physiologic role and functional
assessment of the impact of different variant on the protein.
The two previous reports of PIGH bi-allelic variants demonstrated
GPI deficiencies with their variant. A previously described individual
homozygous for p.(Ser103Pro) was found to have decreased CD55
level as well as a 51% decrease in CD16 on granulocytes compared to
asymptomatic carrier parents.6 In the present series, we showed a
60% decrease in surface CD16 but normal FLAER, CD55 and CD59
levels on homozygous p.(Ser103Pro) granulocytes compared to both
unaffected heterozygous parents.
In summary, our report helps to better delineate the pheno-
typic features of PIGH deficiency, reveals previously unreported
disease-associated symptoms and expands the phenotype including
severe neurodevelopmental manifestations.
TABLE 1 Phenotypic features of individuals with biallelic inactivating variants in PIGH
Individual 1 2A 2B 3 Total Previously published
Hypotonia + + + + 4/4 1/3
DD/ID + +++ +++ + 4/4 3/3
Language delay +++ +++ +++ − 3/4 2/3
Epilepsy/seizures − ++ + + 3/4 3/3
Apraxia + +++ +++ − 3/4 0/3
Feeding difficulties − + + − 2/4 0/3
Facial dysmorphisms − + + − 2/4 2/3
Microcephaly − + + − 2/4 2/3
Strabismus − + + − 2/4 0/3
Musculoskeletal anomalies − ++ + − 2/4 0/3
Autism spectrum disorder or behavioral difficulties ++ − − − 1/4 3/3
Dysarthria + − − − 1/4 0/3
Delayed myelination at brain MRI N/A + + − 2/4 0/3
Normal serum alkaline phosphatase N/A + N/A + 2/4 3/3
Elevated serum iron N/A N/A N/A + 1/4 0/3
Note: N/A = Not Available. DD/ID = Developmental Disability and/or Intellectual Disability. + = mild, ++ = moderate, +++ = severe, − = absent.
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4 | MATERIAL AND METHODS
4.1 | Identification of affected individuals
Individuals were recruited by contact with their clinicians or through
GeneMatcher. Informed written consent was obtained. Ethical
approval was granted by CHU Sainte-Justine Research Ethics Board.
Family 2 was consented to the Manton Center for Orphan Disease
Research Gene Discovery Core protocol (IRB: 10-02-0053).
4.2 | Analysis of PIGH variants
PIGH variant characteristics were extracted from Varsome.10 CADD
scores were calculated on https://cadd.gs.washington.edu.11 PIGH
variants were shown in ProteinPaint from St. Jude Children's Research
Hospital PeCan Data Portal.12
4.3 | Blood fluorescence-activated cell sorting
Blood samples were incubated on ice with GPI-AP markers: PE-CD16
(BioLegend), FITC- CD55, FITC-CD59 (BD PharMingen), and FLAER-Alexa
448 (Cedarlane). Samples were washed using a BD FACSCanto II system
(BD Biosciences). Analysis was carried out with Cytobank software.
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